BidaskClub cut shares of AMAG Pharmaceuticals (NASDAQ:AMAG) from a buy rating to a hold rating in a research note released on Saturday.

AMAG has been the subject of several other reports. Jefferies Group downgraded shares of AMAG Pharmaceuticals from a buy rating to a hold rating and cut their price target for the company from $21.00 to $20.00 in a report on Monday, March 5th. B. Riley reissued a hold rating and set a $16.00 price target on shares of AMAG Pharmaceuticals in a report on Tuesday, January 16th. ValuEngine raised shares of AMAG Pharmaceuticals from a sell rating to a hold rating in a report on Wednesday, February 28th. Cantor Fitzgerald reissued a hold rating and set a $17.00 price target on shares of AMAG Pharmaceuticals in a report on Wednesday, February 14th. Finally, Piper Jaffray reissued a hold rating and set a $20.00 price target on shares of AMAG Pharmaceuticals in a report on Thursday, March 1st. Twelve research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company has a consensus rating of Hold and an average price target of $23.91.

Shares of AMAG stock opened at $19.35 on Friday. AMAG Pharmaceuticals has a 12-month low of $11.93 and a 12-month high of $24.85. The stock has a market cap of $659.62, a P/E ratio of 92.14 and a beta of 0.09. The company has a quick ratio of 1.60, a current ratio of 1.74 and a debt-to-equity ratio of 0.93.

AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings results on Tuesday, February 27th. The specialty pharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.68. AMAG Pharmaceuticals had a negative net margin of 32.66% and a positive return on equity of 0.96%. The firm had revenue of $158.30 million during the quarter, compared to the consensus estimate of $158.84 million. During the same period last year, the firm posted ($0.31) EPS. The firm’s quarterly revenue was up 4.4% on a year-over-year basis. equities research analysts expect that AMAG Pharmaceuticals will post -3.25 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. Balter Liquid Alternatives LLC bought a new position in shares of AMAG Pharmaceuticals in the fourth quarter worth about $120,000. Cubist Systematic Strategies LLC bought a new position in shares of AMAG Pharmaceuticals in the third quarter worth about $197,000. Cambridge Investment Research Advisors Inc. bought a new position in shares of AMAG Pharmaceuticals in the fourth quarter worth about $161,000. Teacher Retirement System of Texas bought a new position in shares of AMAG Pharmaceuticals in the fourth quarter worth about $162,000. Finally, Two Sigma Securities LLC bought a new position in shares of AMAG Pharmaceuticals in the fourth quarter worth about $187,000.

WARNING: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2018/04/22/bidaskclub-lowers-amag-pharmaceuticals-amag-to-hold.html.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.